“o.itemList.length” “this.config.text.ariaShown”
“This.config.text.ariaFermé”
BEVERLY, Massachusetts, USA
AKS-452 is a new FUSION SARS-CoV-2-RBD-Fc protein designed to induce and/or develop antibody titers in patients who oppose the new SARS-CoV-2 coronavirus that causes COVID-19.Preclinical studies in animals have shown physically potent and neutralizing production of antibodies in microgram doses.Akston believes akS-452 is the most complex RBD-Fc fusion protein in advertising progression and that the nature of the structure can offer exclusive benefits over nucleic, viral and inactivated acids.vaccine applicants who are being tested lately. For example, the AKS-452 is designed to be more resilient and made with a singles batch capable of generating loads of millions of doses.The AKS-452 is complemented by Akston’s in vitro diagnosis, the IgG ELISA AntiCoV -Kit IDTM, which quantifies anti-SARS-CoV-2 neutralizing antibody grades in patient serum samples.
Go van Dam, CEO of TRACER, said: “At TRACER, we fully perceive the urgency of accelerating the progression and clinical evaluation of cutting-edge SARS-CoV-2 vaccines.We are very motivated for the Akston team to temporarily move the AKS-452 to the clinic to check its protection and efficacy.»
Todd Zion, ceo of Akston Biosciences, added: “Akston temporarily switched at the start of the pandemic to design a new vaccine against SARS-CoV-2, our Fusion Protein Fc platform.We are very pleased that TRACER plays a key role in the advancement of our number one candidate vaccine through initial clinical trials with a shared sense of urgency and innovation”.
About Akston Biosciences
Akston Biosciences draws on its core expertise in designing new fusion proteins to expand and manufacture new categories of biological treatments for the prevention of type 1 autoimmune diabetes (DT1), ultra-long-acting insulin treatment and vaccines.human and animal health. Founded through the team that developed the world’s first glucose-sensitive clinical insulin at SmartCells, Inc.(sold to Merck
About TRACER Europe B.V.
TRACER Europe BV is a clinical research organization (CRO) specialized in rapid responses for clinical trials of cutting-edge biological treatments, as well as complex methodologies of nuclear and optical molecular imaging.TRACER and its partners provide their customers with the experience, infrastructure and ability to temporarily generate inhuman clinical knowledge.This provides maximum accurate human knowledge to know if the tested compound reaches the target tissue, making clinical trials more cost-effective and products more temporarily reaching the market.For more information about TRACER, tap info tracercro.com or www.tracercro.com
attachment file
AKS-452